Logo

Roche's Xofluza (baloxavir marboxil) Receives CHMP's Recommendation for Approval to Treat Influenza

Share this

Roche's Xofluza (baloxavir marboxil) Receives CHMP's Recommendation for Approval to Treat Influenza

Shots:

  • The EMA’s CHMP has recommended the approval of Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged ≥12yrs. Xofluza has also been recommended for approval as a preventive treatment (post-exposure prophylaxis) of influenza in individuals aged ≥12yrs.
  • The CHMP recommendation is based on the results of the P-III CAPSTONE-1- CAPSTONE-2 and BLOCKSTONE studies. The company is expecting the EC’s final decision in approval in the near future
  • Xofluza is the first in a class of antivirals designed to inhibit the cap-dependent endonuclease protein and is available in the US and in several other countries for influenza types A and B

­ Ref: Roche | Image: Roche

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions